Role of Psychedelics in Treatment-Resistant Depression.
Shubham Kamal, Manish Kumar Jha, Rajiv Radhakrishnan
The Psychiatric clinics of North America June 1, 2023 DOI: 10.1016/j.psc.2023.02.004 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Ayahuasca Depression DMT LSD MDMA Psilocybin |
| Keywords | Psychedelics hallucinogens Entheogens Psychoactive compounds Psychiatric interventions Mood disorder treatments Pharmacology psychopharmacology Drug mechanisms Pharmaceutical science |
| Citations | 32 |
| Key findings | Evidence for classic psychedelics in treatment-resistant depression is limited but early studies show promising results, and the field may be subject to a hype bubble. |
Abstract
There is increasing interest in exploring the therapeutic potential of psychedelics in treatment-resistant depression (TRD). Classic psychedelics (such as psilocybin, LSD, ayahuasca/DMT), and atypical psychedelics (such as ketamine) have been studied in TRD. The evidence for the classic psychedelics TRD is limited at the present time; early studies however show promising results. There is also recognition that psychedelic research may be subject to a "hype bubble" at the present time. Future studies focused on delineating necessary ingredients of psychedelic treatments and the neurobiological basis of their effects, will help pave the way for the clinical use of these compounds.